BioCentury | Oct 24, 2020
Finance

Oct. 23 Quick Takes: RA Capital’s $461M new fund; plus venture rounds for Sirnaomics, 3D Medicines, Zhaoke, Orbus, Araris

New $461M venture fund for RA RA Capital raised $461 million for its Nexus Fund II, its second venture fund that like 2019’s $300 million Nexus I Fund will invest in private companies backed by the...
BioCentury | Oct 23, 2020
Product Development

Fresh $20M allows Azura to move lead candidate into pivotal testing for major cause of dry eye

With a new $20 million financing that doubles what the company has raised to date, Israel’s Azura will be able to advance its lead program into a registrational study to address a major cause of dry...
BioCentury | Oct 21, 2020
Deals

Seeking programs underserved by traditional VCs, MD Anderson launches fund to support trials

A new fund co-founded by MD Anderson is intended to support early development of a subset of drug candidates that are not served by traditional venture capital or biopharmas, but which the cancer research...
BioCentury | Oct 17, 2020
Deals

Oct. 16 Quick Takes: Dren Bio’s $60M series A; plus Roche, Synairgen, Astellas-iota and more

Dren Bio raises $60M series A to develop cell-depleting engineered proteinsDren Bio raised a $60 million series A round led by SR One and Taiho Ventures, LLC, with participation from existing investors...
BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

Dean Li will take over a Merck Research Laboratories that has been transformed by Roger Perlmutter over the past seven years, guiding a pharma that had been struggling with a patent cliff to the company...
BioCentury | Sep 5, 2020
Product Development

With second approval of year, Blueprint readies to put partner Genentech into play

Two months after partnering with Roche in one of the year’s biggest deals, Blueprint has its second FDA approval of the year with pralsetinib in NSCLC. The biotech believes the efficacy and safety...
BioCentury | Aug 21, 2020
Finance

Data Bytes: biotechs that could face pressure to de-list due to foreign auditing

More than a dozen life sciences companies appear on a Public Company Accounting Oversight Board list of U.S.-traded companies audited by firms based in countries where the board’s ability to conduct inspections is impaired: China,...
BioCentury | Aug 15, 2020
Finance

As CBMG moves to complete go-private deal, pressure on U.S.-listed Chinese companies mounts in Washington

While CBMG’s $383 million take private deal was put in motion before U.S. officials further ratcheted up pressure on U.S- listed Chinese companies, the move highlights the trade-offs Chinese companies face in considering where to...
BioCentury | Aug 13, 2020
Finance

Cell analysis company Mission Bio aiming to scale with $70M series C

Two years after generating its first revenues, single-cell analysis and profiling company Mission Bio hopes to use its new $70 million series C round to scale its commercial operations broadly to help...
BioCentury | Jul 15, 2020
Product Development

July 14 Quick Takes: Cytokinetics accesses cash via royalty, licensing deals; plus Junshi-Revitope and Sanofi-MD Anderson

Cytokinetics in deals with Chinese biotech, investor Cytokinetics Inc. (NASDAQ:CYTK) said it could receive $250 million in committed capital and $200 million in milestones via a series of deals with Ji Xing Pharmaceuticals Ltd. and...
Items per page:
1 - 10 of 11434